Methods of treating cancers with her3 antisense...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/712 (2006.01) C12N 15/113 (2010.01) A61P 35/00 (2006.01) C07H 21/04 (2006.01)

Patent

CA 2758005

One aspect of the invention provides methods for treating cancers which are resistant to treatment with a protein tyrosine kinase inhibitor by co-treatment with the protein tyrosine kinase inhibitor and one or more antisense oligomers that reduce the expression of HER3 and/or HER2 and/or EGFR. Another aspect of the invention provides methods for treating cancers by co-treatment with an inhibitor of HER2 and one or more antisense oligomers that reduce the expression of HER3.

Selon un aspect, l'invention porte sur des procédés de traitement de cancers qui sont résistants à un traitement par un inhibiteur de protéine tyrosine kinase, par un co-traitement avec l'inhibiteur de protéine tyrosine kinase et un ou plusieurs oligomères anti-sens qui réduisent l'expression de HER3 et/ou HER2 et/ou EGFR. Un autre aspect de l'invention porte sur des procédés pour traiter des cancers par un co-traitement avec un inhibiteur de HER2 et un ou plusieurs oligomères anti-sens qui réduisent l'expression de HER3.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Methods of treating cancers with her3 antisense... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating cancers with her3 antisense..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cancers with her3 antisense... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1420383

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.